CD8A and neoplasm: Compared to untreated and control oligo-treated, tumor-bearing mice, TLR9 agonist selectively induced the proliferation of TLR9-expressing splenocytes, including B220+ B cells (p<0.001), Cd11c+B220+NK1.1-CD80+ activated pDCs (p<0.001) and CD11c+B220-NK1.1+ NKDCs (p<0.05) but reduced the percentage of CD3+CD4+ and CD3+CD8+ T cells (p<<0.001) (Table 1).